- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04001049
Glycemic Variability: Prognostic Impact on Acute Ischemic Stroke (GLIAS-III)
July 6, 2020 updated by: Instituto de Investigación Hospital Universitario La Paz
Glycemic Variability: Prognostic Impact on Acute Ischemic Stroke and Impact of the Corrective Treatment for Hyperglycemia.
This is a multicenter observational clinical study in patients with acute ischemic stroke.
The main objective is to evaluate the impact of glycemic variability (GV) on stroke outcome (mortality, functional recovery) of patients with acute ischemic stroke.
Glycemic variability will be assessed using a subcutaneous device for continuous glycaemia motorization during 96 hours; also capillar glycaemia will be measured every 6 hours.
Study Overview
Status
Unknown
Conditions
Detailed Description
10 different hospitals in Spain will participate in this study, recruiting a total of 340 patients.
Once the informed consent form is signed, the subcutaneous device for continuous glycaemia motorization will be implanted and demographic, comorbidities and treatments of every patient will be registered.
During the first 96 hours, capillar glycaemia, NIHSS scale, HbA1C levels, cerebral recanalization treatment and glycaemia correcting treatments will also be reported.
In the following days (7, 30 and 90 days after stroke) modified Rankin Scale, NIHSS scale and stroke secondary prevention treatments will be evaluated.
At day 90, a new measure of HbA1C will be done.
Study Type
Observational
Enrollment (Anticipated)
340
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Blanca Fuentes Gimeno
- Phone Number: +34917277444
- Email: blanca.fuentes@salud.madrid.org
Study Contact Backup
- Name: Elena de Celis Ruiz
- Phone Number: +34917277444
- Email: elena.decelis.ruiz@idipaz.es
Study Locations
-
-
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Contact:
- Silvia Pastor Yvorra
- Phone Number: 917277444
- Email: silviamanuela.pastor@salud.madrid.org
-
Contact:
- Blanca Fuentes Gimeno
- Phone Number: 917277444
- Email: blanca.fuentes@salud.madrid.org
-
Principal Investigator:
- Blanca Fuentes Gimeno
-
Sub-Investigator:
- Silvia Pastor Yvorra
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients > 18 years old presenting with acute ischemic stroke of less than 24 hours of evolution
Description
Inclusion Criteria:
- > 18 years old
- Inclusion less than 24 hours from ischemic stroke
- Functional independence prior to stroke
- Signed informed consent
Exclusion Criteria:
- Transient cerebral ischemia
- Prevision of need to perform a magnetic resonance within the first 96 hours from inclusion
- Concomitant severe or deadly disease that may interfere with study follow-up during 3 months from stroke
- Current drug or alcohol abuse that may interfere with study follow-up
- Participation in a clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic variation impact in mortality of patients with acute ischemic stroke
Time Frame: 3 months from stroke
|
Intrahospital mortality
|
3 months from stroke
|
Glycemic variation impact in functional status of patients with acute ischemic stroke
Time Frame: 3 months from stroke
|
Modified Rankin Scale. This scale measures degree of disability/dependence after a stroke. 0- No symptoms
|
3 months from stroke
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of glycemic variation in mortality in diabetic patients with acute ischemic stroke.
Time Frame: 3 months from stroke
|
Intrahospital mortality
|
3 months from stroke
|
Impact of glycemic variation in functional status in diabetic patients with acute ischemic stroke.
Time Frame: 3 months from stroke
|
Modified Rankin Scale. This scale measures degree of disability/dependence after a stroke. 0- No symptoms
|
3 months from stroke
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Blanca Fuentes Gimeno, Hospital Universitario La Paz
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 30, 2020
Primary Completion (Anticipated)
June 30, 2021
Study Completion (Anticipated)
June 30, 2021
Study Registration Dates
First Submitted
May 22, 2019
First Submitted That Met QC Criteria
June 26, 2019
First Posted (Actual)
June 27, 2019
Study Record Updates
Last Update Posted (Actual)
July 7, 2020
Last Update Submitted That Met QC Criteria
July 6, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLIAS-III
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
-
Medical University of ViennaCompleted
-
Addis Ababa UniversityCompletedHyperglycemia, Postprandial
-
University of Eastern FinlandFinnsugar LtdCompletedHyperglycemia, PostprandialFinland